Gujarat Themis Biosyn QIP Plan: ₹2,500 Cr in 2026 Ballot

What the company is asking shareholders to approve

Gujarat Themis Biosyn Limited has initiated a postal ballot to seek shareholder approval for fundraising and certain governance changes. The company is seeking authorisation to raise up to ₹1,000 crore through a Qualified Institutions Placement (QIP). It is also seeking a separate mandate to issue up to ₹1,500 crore via debt securities such as Non-Convertible Debentures (NCDs) through private placement. Alongside the capital-raising proposals, the notice includes a special resolution to amend the Articles of Association (AoA). The stated aim is to streamline share issuance processes by removing mandatory valuation requirements where such valuation is not legally mandated. These items are being placed before members for approval through remote e-voting.

Postal ballot and remote e-voting window

The remote e-voting is being conducted through Central Depository Services (India) Limited (CDSL). As disclosed, the e-voting window opened on July 24, 2026 at 9:00 a.m. IST and is scheduled to close on August 22, 2026 at 5:00 p.m. IST. The postal ballot structure means shareholders do not vote at a physical meeting, but through the electronic voting system during the specified window. The company has positioned the fundraising as being linked to growth opportunities and repayment of existing borrowings. It has asked shareholders to pass special resolutions covering the equity raise, the debt issuance mandate, and the AoA amendment.

Cut-off date eligibility: two dates referenced

The notice details include cut-off dates to determine who is eligible to vote. In one disclosure, shareholders holding equity as of the July 17, 2026 cut-off date are described as eligible to vote. Another part of the provided information mentions a cut-off date of July 10, 2026 for voting eligibility. Investors typically need to check the specific notice and depository records tied to their holdings to confirm eligibility as per the relevant cut-off date referenced in the communication they received. The voting deadline is consistently stated as August 22, 2026 at 5:00 p.m. IST.

QIP plan: size and stated use of proceeds

Under the QIP proposal, Gujarat Themis Biosyn is seeking approval to raise up to ₹1,000 crore by issuing equity shares to qualified institutional buyers. The company has indicated that the fundraising is intended to support growth opportunities. It has also stated that proceeds may be used to repay existing borrowings. A QIP is a common route for listed companies to raise equity capital from institutional investors, but the exact pricing, timing, and investor participation depend on market conditions and final approvals. The postal ballot seeks the enabling approval, after which the company can execute the issuance within the authorised limit.

Debt issuance mandate: NCDs and other securities

Separately, the company is seeking member authorisation for issuing up to ₹1,500 crore of NCDs or other debt securities via private placement. This authorisation typically provides flexibility to raise debt in one or more tranches, subject to applicable rules. The proposal indicates the board may issue such debt instruments within the approved limit if shareholders pass the special resolution. The article data does not specify the tenure, coupon, security, or whether the debt would be rated or secured. Those details, if any, would generally be disclosed closer to execution.

AoA amendment: valuation requirement to be removed where not mandated

One of the special resolutions covers amending the Articles of Association. The stated purpose is to streamline share issuance processes. Specifically, the proposal includes removing mandatory valuation requirements in situations where valuation is not legally mandated. Companies often align internal governance documents with evolving regulatory frameworks and capital-raising practices, but the amendment still requires shareholder approval through a special resolution. The notice positions this as a governance update linked to capital issuance efficiency.

Key dates and figures at a glance

Other corporate updates disclosed alongside

The provided information also mentions that Gujarat Themis Biosyn amicably resolved a commercial arbitration dispute with Optimus Drugs Private Limited. The company stated that the mutual settlement resulted in the disposal of the arbitration proceedings. In another update included in the data, the company indicated it had received shareholder approval to raise funds through a QIP of equity shares via postal ballot. It reported that the special resolution was passed with 99.9762% of votes cast in favour. The dataset does not provide the date of that vote result in the text shared here.

Trading window closures cited in the disclosures

The article data includes references to trading window closures under SEBI (Prohibition of Insider Trading) Regulations, 2015. Gujarat Themis Biosyn announced closure of its trading window from April 1, 2026 for its Q4 FY26 financial results. Separately, it also stated the trading window would be closed from October 1, 2025 for the quarter ending September 30, 2025, reopening 48 hours after the board declares the results. Such closures are standard compliance measures restricting dealing in securities by insiders during sensitive periods.

Stock and company identifiers mentioned

The provided information lists the company’s exchange identifiers as BSE: 506879 and NSE: GUJTHEM. It also includes multiple price references from different points in time, including a value of ₹373.00 as on May 4, 2026 (16:00 IST), and another snapshot indicating the stock moved down by -4.74% from a previous close of ₹424.30 to a last traded price of ₹404.20. Another market data line cites ₹401.20 on NSE at a specified timestamp. These figures reflect different dates and sources included in the dataset.

What investors typically watch next

With the e-voting window running through August 22, 2026, the immediate milestone is the declaration of postal ballot results, expected by August 25, 2026 as stated. Shareholders and market participants generally track whether the special resolutions pass and the extent of voting support. If approvals are secured, the next disclosures would typically relate to the execution of the QIP and any debt issuance, along with final terms and timing. The AoA amendment outcome will also matter for how efficiently the company can manage future share issuances in situations where valuation is not legally required.